Related Experiment Video
Updated: Jul 11, 2026

Determination of Continuity Index Values in Atrial Fibrillation Ablation with Proactive Esophageal Cooling
Published on: April 19, 2024
Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome
Ioannis Rizos1, Sotirios Tsiodras, Angelos G Rigopoulos
12nd Academic Department of Cardiology, Attikon University Hospital, University of Athens Medical School, 19 Kentauron Street, 15237 Filothei, Athens, Greece. ioannis.c.rizos@otenet.gr
Insights
Low interleukin-2 (IL-2) levels on admission predict successful amiodarone cardioversion in recent-onset atrial fibrillation (AF) patients with cardiovascular conditions. This finding underscores inflammation
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- Recent-onset atrial fibrillation (AF) poses a significant clinical challenge.
- Inflammation is increasingly recognized as a factor in AF pathophysiology.
- Predictors of successful pharmaceutical cardioversion require further elucidation.
Purpose of the Study:
- To investigate the relationship between inflammatory markers and the success of amiodarone cardioversion in patients with recent-onset AF.
- To identify potential predictors of successful cardioversion in a specific patient cohort.
Main Methods:
- Eighty-six patients with symptomatic recent-onset AF and comorbidities (hypertension and/or coronary artery disease) were studied.
- Standardized protocol included echocardiography and measurement of interleukin-2 (IL-2), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hsCRP) at admission and 48 hours.
- Intravenous amiodarone was administered, and cardioversion success was assessed by 48 hours.
Main Results:
- Seventy patients (81%) cardioverted to sinus rhythm within 48 hours.
- Higher median serum IL-2 levels on admission were observed in non-cardioverted patients (P=0.002).
- At 48 hours, non-cardioverted patients had significantly higher IL-6 (P=0.005) and hsCRP (P=0.001) levels.
- Lower admission IL-2 levels independently predicted successful cardioversion (OR: 0.154, P=0.004).
Conclusions:
- Low serum IL-2 levels on admission are associated with successful amiodarone cardioversion in recent-onset AF patients with hypertension and/or coronary artery disease.
- This suggests a role for inflammation in the success of pharmaceutical cardioversion for AF.
- These findings may have prognostic and therapeutic implications for AF management.
Abstract:
We evaluated the hypothesis that a relationship exists between inflammation and the outcome of pharmaceutical cardioversion with amiodarone in recent onset atrial fibrillation. We studied 86 patients with symptomatic recent onset AF and coexisting hypertension and/or chronic stable coronary artery disease. All study participants underwent evaluation with a standardized protocol including echocardiography, cytokine level measurement [interleukin-2 (IL-2), interleukin-6 (IL-6) and high sensitivity C reactive protein (hsCRP)] on admission and at 48h, and administration of intravenous amiodarone. By 48h, 70 patients cardioverted to sinus rhythm. Median serum IL-2 levels on admission were higher in non-cardioverted compared to cardioverted patients (P=0.002). At 48h, non-cardioverted had significantly higher IL-6 (P=0.005) and hsCRP values (P=0.001) compared to cardioverted. Multivariate logistic regression analysis showed that lower IL-2 admission levels were a powerful independent predictor for successful cardioversion (OR: 0.154, 95% CI: 0.043-0.552, P=0.004). In patients with hypertension and/or chronic stable coronary artery disease and symptomatic recent onset AF, low serum IL-2 levels on admission are associated with successful cardioversion with amiodarone. This observation highlights the role of inflammation in AF and might have further prognostic and therapeutic implications.
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Myocarditis II: Clinical Features and Diagnostic Tests
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Pericarditis II: Clinical Features and Diagnostic Tests
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
